A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer

被引：0
|
作者：
Hammad, N.
Philip, P. A.
Shields, A. F.
Sarkar, F. H.
Abruzzese, J. L.
Kaseb, A. O.
Javle, M. M.
Varadhachary, G. R.
Wolff, R. A.
El-Rayes, B. F.
机构：
[1] Karmanos Canc Ctr, Detroit, MI USA
[2] Wayne State Univ, Detroit, MI USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15540
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15540
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
    Semrad, Thomas
    Barzi, Afsaneh
    Lenz, Heinz-Josef
    Hutchins, Irene M.
    Kim, Edward J.
    Gong, I-Yeh
    Tanaka, Michael
    Beckett, Laurel
    Holland, William
    Burich, Rebekah A.
    Snyder-Solis, Leslie
    Mack, Philip
    Lara, Primo N., Jr.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 518 - 524
  • [22] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
    Thomas Semrad
    Afsaneh Barzi
    Heinz-Josef Lenz
    Irene M. Hutchins
    Edward J. Kim
    I-Yeh Gong
    Michael Tanaka
    Laurel Beckett
    William Holland
    Rebekah A. Burich
    Leslie Snyder-Solis
    Philip Mack
    Primo N. Lara
    International Journal of Clinical Oncology, 2015, 20 : 518 - 524
  • [23] A phase II study of gemcitabine, oxaliplatin, and erlotinib (GEMOX-T) combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic pancreatic cancer
    Yun, Jina
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Kim, Hyun Jung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Soong Kyu
    Won, Jong-Ho
    Hong, Dae Sik
    Park, Hoe Sook
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
  • [25] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Suee Lee
    Hyuk Chan Kwon
    Gyeong Won Lee
    Seil Go
    Myoung Hee Kang
    Young Joo Cha
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 2371 - 2376
  • [26] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
  • [27] A Phase II Study of Gemcitabine and Irinotecan in Patients With Locally Advanced or Metastatic Bladder Cancer
    Chaudhary, Uzair B.
    Verma, Nitin
    Keane, Thomas
    Gudena, Vinay
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 188 - 193
  • [28] Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2)
    André, T
    Noirclerc, M
    Hammel, P
    Meckenstock, R
    Landi, B
    Cattan, S
    Selle, F
    Codoul, JF
    Guerrier-Parmentier, B
    Mokhtar, R
    Louvet, C
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (8-9): : 645 - 650
  • [29] Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer
    Yaman Suleiman
    Amit Mahipal
    David Shibata
    Erin M. Siegel
    Helen Jump
    William J. Fulp
    Gregory M. Springett
    Richard Kim
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 481 - 487
  • [30] Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
    Van Cutsem, E.
    Li, C-P
    Nowara, E.
    Aprile, G.
    Moore, M.
    Federowicz, I.
    Van Laethem, J-L
    Hsu, C.
    Tham, C. K.
    Stemmer, S. M.
    Lipp, R.
    Zeaiter, A.
    Fittipaldo, A.
    Csutor, Z.
    Klughammer, B.
    Meng, X.
    Ciuleanu, T.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2067 - 2075
12345